No GH-axis peptide is a weight-loss drug. In the longest controlled trial of a sermorelin-class peptide, lean mass rose in men over 16 weeks while fat mass did not change significantly. The class works on visceral fat over months, not the scale over weeks.
Peptides marketed for weight loss fall into two groups that get confused constantly. GH-axis peptides such as sermorelin and tesamorelin change body composition slowly, mostly by trimming visceral fat and protecting lean mass. The GLP-1 medications are the evidence-based weight-loss drug class, and they work through appetite and satiety, a different mechanism entirely. Buying one expecting the other is the most common mistake people make here.
- GH-axis peptides are not weight-loss drugs. They change body composition gradually, not scale weight quickly
- In the longest controlled sermorelin-class trial, lean mass rose in men over 16 weeks while fat mass did not change significantly [1]
- Tesamorelin has the strongest fat-loss evidence in the class, and it is specific to visceral and abdominal fat [3][4]
- For direct weight loss, the GLP-1 medications (semaglutide, tirzepatide) are the evidence-based class and work through a different mechanism
- The right tool depends on the goal: GLP-1 for weight, GH-axis peptides for visceral fat and lean mass
This guide sorts which peptides do what, over what timeframe, and for whom. The honest version is less exciting than the marketing and more useful. It sits inside the broader picture of GH-axis peptide therapy, and if you are comparing options head to head, the best peptides for weight loss breakdown ranks them by goal.
Peptides Do Not Cause Weight Loss. They Change Body Composition.
The distinction between weight and body composition is the whole story. Body composition is the ratio of fat to lean mass. Scale weight is a single number that hides that ratio. GH-axis peptides act on the ratio, slowly, and can leave the scale nearly unchanged while the waistline moves.
The clearest data comes from a randomized placebo-controlled trial of a GHRH analog given nightly for 16 weeks to adults aged 55 to 71. Lean body mass increased in men and skin thickness increased in both sexes, but fat mass did not change significantly across the study [1]. That is a body composition effect, not weight loss, and reporting it as weight loss overstates what the molecule does.
The GH-Axis Peptides and Visceral Fat
Where GH-axis peptides earn their fat-loss reputation is visceral fat, the metabolically active fat packed around the organs. Pooled human data on GHRH-analog therapy shows reduction in visceral fat developing over roughly 6 months [2]. Tesamorelin, the one FDA-approved peptide in the class, was approved specifically because it reduces visceral and abdominal fat.
In the tesamorelin trials, patients with excess abdominal fat saw meaningful reduction in visceral adipose tissue over 26 weeks, an effect large enough to earn an FDA indication for HIV-associated lipodystrophy [3][4][7]. Sermorelin acts on the same axis more gently, which is why its body composition effect is real but slower and smaller [5].
| Peptide | Body composition effect | Evidence | Timeframe |
|---|---|---|---|
| Sermorelin | Lean mass gain in men; no significant fat mass change | Controlled trial [1] | 16 weeks+ |
| Tesamorelin | Visceral and abdominal fat reduction | Phase 3 trials [3][4] | 26 weeks |
| GHRH analogs (class) | Visceral fat reduction | Pooled human data [2] | ~6 months |
| GLP-1 (semaglutide, tirzepatide) | Substantial total body weight reduction | Evidence-based weight-loss class |
GH-axis peptides move visceral fat and lean mass. The GLP-1 class moves total weight. They are not competitors; they solve different problems.
What GH-Axis Peptides Will Not Do
Setting expectations honestly is the difference between satisfaction and a wasted six months. Sermorelin will not produce rapid scale weight loss. It will not override a caloric surplus. And it does not push a normal GH axis higher, because somatostatin feedback actively prevents that [6].
- It will not produce fast scale weight loss; the fat effect is visceral and gradual
- It will not work without a diet and training foundation underneath it
- It will not raise GH in someone whose axis is already normal [6]
- It is not a GLP-1 substitute for someone who needs to lose a large amount of weight
- It is banned in tested sport, so it is not an option for competitive athletes [8]
The Evidence-Based Weight-Loss Class Is GLP-1
If the goal is losing a substantial amount of body weight, the honest answer is that GLP-1 receptor agonists are the medication class with the strongest evidence for that specific outcome. Semaglutide and tirzepatide reduce appetite and slow gastric emptying, which lowers calorie intake. That is a fundamentally different mechanism from stimulating the pituitary.
A GH-axis peptide and a GLP-1 medication are not doing the same job. One reshapes the fat-to-lean ratio and defends muscle. The other drives down total intake and total weight. For someone carrying significant excess weight, starting with a GH-axis peptide and expecting scale movement is the wrong tool for the goal. The full side-by-side is laid out in peptides vs GLP-1.
| Goal | Best-matched tool |
|---|---|
| Lose a large amount of total body weight | GLP-1 medication under medical supervision |
| Reduce visceral and abdominal fat specifically | GH-axis peptide (tesamorelin has the strongest evidence) |
| Preserve or add lean mass while dieting | GH-axis peptide plus resistance training |
| Fast scale weight loss in weeks | Not GH-axis peptides |
Get Thin MD pairs sermorelin with physician-supervised medical weight loss, so the fat-loss goal and the body composition goal are handled under one program rather than one peptide asked to do both.
Realistic Expectations Over Six Months
For a candidate with a documented low or low-normal IGF-1, the realistic outcome from a GH-axis peptide over 6 months is a modest reduction in visceral fat, better slow-wave sleep, and preserved or slightly increased lean mass when paired with training and adequate protein [1][2]. The scale may barely move. The waist measurement is the more honest metric.
- Draw a baseline IGF-1 before starting so the response is measurable
- Track waist circumference under identical conditions, not scale weight alone
- Keep protein adequate and train against resistance to convert GH signaling into lean mass
- Retest IGF-1 at 90 days to confirm the dose is working
- Judge results at 6 months, not at 4 to 12 weeks
Bottom Line
Frequently Asked Questions
Do peptides work for weight loss?
Not the way people expect. GH-axis peptides such as sermorelin and tesamorelin change body composition by reducing visceral fat and preserving lean mass over months, but they do not drive rapid scale weight loss. In a controlled 16-week trial of a sermorelin-class peptide, lean mass rose in men while fat mass did not change significantly [1]. For direct weight loss, the GLP-1 class has the stronger evidence.
Which peptide is best for losing belly fat?
Tesamorelin has the strongest evidence for reducing visceral and abdominal fat, which is why it earned an FDA indication for HIV-associated lipodystrophy [3][4][7]. GHRH-analog therapy as a class reduces visceral fat over roughly 6 months in pooled human data [2]. Sermorelin acts on the same axis more gently and slowly.
Is sermorelin a weight-loss drug?
No. Sermorelin is a GHRH analog that stimulates the pituitary and changes body composition gradually. It does not produce fast scale weight loss and does not override a caloric surplus. Its measurable effect is on visceral fat and lean mass over a 6-month protocol, not on total weight over weeks [1][2].
Are peptides better than GLP-1 for weight loss?
For losing a substantial amount of total body weight, GLP-1 medications such as semaglutide and tirzepatide are the evidence-based class and work through appetite and satiety. GH-axis peptides target visceral fat and lean mass through a different mechanism. They solve different problems, so the better choice depends on whether your goal is total weight or body composition.
Can you combine peptides with a weight-loss program?
Yes, and that is often the sensible structure. A GH-axis peptide can preserve lean mass and target visceral fat while a supervised weight-loss program, including a GLP-1 medication where appropriate, drives total weight down. Some providers integrate both under one physician-managed plan rather than asking a single peptide to do everything.
How long before peptides affect body composition?
Slowly. IGF-1 rises within about 2 weeks of correct nightly dosing, but body composition changes accumulate over months. Visceral fat reduction in GHRH-analog data developed over roughly 6 months [2], and the controlled sermorelin-class trial ran 16 weeks before measuring lean mass gains [1]. Judge results at 6 months, not weeks.
References
- Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women Journal of Clinical Endocrinology & Metabolism, 1997. PMID: 9141536. https://pubmed.ncbi.nlm.nih.gov/9141536/
- Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies Growth Hormone & IGF Research, 2015. PMID: 25555516. https://pubmed.ncbi.nlm.nih.gov/25555516/
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data Journal of Clinical Endocrinology & Metabolism, 2010. PMID: 20554713. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency BioDrugs, 1999. PMID: 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PMC2699646. https://pmc.ncbi.nlm.nih.gov/articles/PMC2699646/
- EGRIFTA SV (tesamorelin) for injection: full prescribing information DailyMed, U.S. National Library of Medicine, 2025. FDA-approved labeling. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
